Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
Clin Infect Dis
    May 2026
  1. LEE TH, Bhattacharya D, Kim HN
    Don't Drop the B: Risk of Hepatitis B Virus Infection and Reactivation in the Era of Tenofovir-Sparing Regimens for Treatment and Prevention of HIV.
    Clin Infect Dis. 2026 May 27:ciag322. doi: 10.1093.
    >> Share

  2. FAMIGLIETTI AM, Drammeh S, Vo-Quang E, Dibba B, et al
    Field performance and acceptability of the hepatitis B core-related antigen rapid diagnostic test (HBcrAg-RDT) for detecting high viral load among pregnant women in The Gambia (PROTECT-B).
    Clin Infect Dis. 2026 May 12:ciag311. doi: 10.1093.
    >> Share

    April 2026
  3. KILLANDER MOLLER I, Wagner P, Brannstrom J, Backdahl T, et al
    Renal and Cardiovascular Complications Following Type 2 Diabetes Mellitus in People With and Without HIV: Data from Cohort Study on Morbidity and HIV in Sweden (COSMOHS) between 2010-2024.
    Clin Infect Dis. 2026 Apr 18:ciag261. doi: 10.1093.
    >> Share

  4. HOFFMAN R, Brummel S, Pinilla M, Malonga G, et al
    Hypertension in a randomized trial of dolutegravir- versus efavirenz-based antiretroviral therapy in pregnant and postpartum women with HIV.
    Clin Infect Dis. 2026 Apr 13:ciag245. doi: 10.1093.
    >> Share

  5. WYNCOLL J, Kamolrattana R, Archary M, Mujuru HA, et al
    Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial.
    Clin Infect Dis. 2026 Apr 10:ciag232. doi: 10.1093.
    >> Share

  6. SHUMAKER AH, Bhimraj A, Bedimo R, Cheng VC, et al
    2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults.
    Clin Infect Dis. 2026 Apr 1:ciaf680. doi: 10.1093.
    >> Share

    March 2026
  7. KOETHE JR, Lake JE, Kantor A, Smeaton L, et al
    A 48-week, Randomized Controlled Trial of Doravirine for Individuals with HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391).
    Clin Infect Dis. 2026 Mar 18:ciag196. doi: 10.1093.
    >> Share

  8. LANDOVITZ RJ, Pinedo Y, Hinestrosa F, Crofoot GE, et al
    Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study.
    Clin Infect Dis. 2026 Mar 14:ciag171. doi: 10.1093.
    >> Share

  9. MAZZITELLI M, Parczewski M, Burger D, Wensing A, et al
    Virological Failure on Long-Acting Injectable Cabotegravir and Rilpivirine: An Analysis of Subtypes, Drug Levels, Resistance, and Therapeutic Implications.
    Clin Infect Dis. 2026 Mar 11:ciag046. doi: 10.1093.
    >> Share

  10. DORWARD J, Masombuka X, Lewis L, Pastellides C, et al
    Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-Identified Data From South Africa.
    Clin Infect Dis. 2026 Mar 4:ciag155. doi: 10.1093.
    >> Share

    February 2026
  11. MOHAREB AM, Boyd A
    Hepatitis B Virus Reactivation in People With HIV After Treatment With Non-hepatitis B virus-active Antiretroviral Therapy.
    Clin Infect Dis. 2026 Feb 24:ciag002. doi: 10.1093.
    >> Share

  12. DENYER RV, Tate JP, Benator DA, Lim JK, et al
    Hepatitis B Reactivation in a US Cohort of People With Human Immunodeficiency Virus and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity.
    Clin Infect Dis. 2026 Feb 24:ciag001. doi: 10.1093.
    >> Share

  13. SPINELLI MA, Ewart LD, Ross EJ, Heise MJ, et al
    Point-of-Care Urine Tenofovir Drug-Level Feedback Counseling Improves Long-term PrEP Adherence for U.S. MSM in Pilot RCT.
    Clin Infect Dis. 2026 Feb 10:ciag080. doi: 10.1093.
    >> Share

  14. GREEN AS, Li JZ, Sax PE
    Is Two Drug Therapy with Dolutegravir and Lamivudine an Appropriate Option for People with HIV and Historic Lamivudine Resistance?
    Clin Infect Dis. 2026 Feb 10:ciag061. doi: 10.1093.
    >> Share

  15. DE LAGARDE M, De Miguel R, Sigcha MA, Blanco JL, et al
    Impact of Proviral-DNA M184V/I on 96-Week Outcomes of DTG/3TC Maintenance Therapy: Results from the VOLVER Clinical Trial.
    Clin Infect Dis. 2026 Feb 10:ciag060. doi: 10.1093.
    >> Share

    January 2026
  16. FONCILLAS A, Ambrosioni J, Sempere A, Berrocal L, et al
    Hepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles.
    Clin Infect Dis. 2026 Jan 14:ciag023. doi: 10.1093.
    >> Share

  17. MAKINSON A, Bani-Sadr F, Palich R, Montes B, et al
    Switch to BIC/TAF/FTC or DTG + TDF/FTC in virologically suppressed PWH: outcomes in real-world setting with and without tenofovir resistance.
    Clin Infect Dis. 2026 Jan 9:ciaf726. doi: 10.1093.
    >> Share

  18. APPA A, Steiner G, Baral S, Riley E, et al
    Integrating HIV and Stimulant Use Disorder Treatment: A Pilot Implementation Effectiveness Trial of Contingency Management in HIV Care.
    Clin Infect Dis. 2026 Jan 8:ciag006. doi: 10.1093.
    >> Share

  19. OBENG BM, Hutchinson J, Shaik A, Chetchotisakd P, et al
    Regional variations of rates and determinants of drug resistance mutations in people failing first-line therapy for HIV-1: a substudy from the D2EFT phase 3b/4 clinical trial.
    Clin Infect Dis. 2026 Jan 3:ciaf739. doi: 10.1093.
    >> Share

    December 2025
  20. OSUALA EC, Nkuhairwe IN, Letsoalo MP, Naidoo K, et al
    Pharmacokinetics of Twice-Daily Tenofovir Alafenamide In Adults with HIV-Associated TB on BIC/FTC/TAF and Rifampicin.
    Clin Infect Dis. 2025 Dec 30:ciaf732. doi: 10.1093.
    >> Share

  21. CALDERIN JM, Resendiz-Galvan JE, Abdelgawad N, Davis A, et al
    Pharmacokinetics of Dexamethasone in Tuberculous Meningitis.
    Clin Infect Dis. 2025 Dec 18:ciaf642. doi: 10.1093.
    >> Share

    November 2025
  22. OLCOTT F, Oddie PD, Barlow MJ, Mamarelis A, et al
    Hepatitis B reactivation following switch away from tenofovir-containing anti-retroviral therapy in people living with HIV: A case series and lessons for practice.
    Clin Infect Dis. 2025 Nov 19:ciaf634. doi: 10.1093.
    >> Share

  23. KURIAKOSE S, Tseng A, Boyd S, Gibbons S, et al
    International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness.
    Clin Infect Dis. 2025 Nov 3:ciaf606. doi: 10.1093.
    >> Share

    October 2025

  24. Retraction and replacement of: Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019-Associated Hospitalization Prevention: A Population-based Cohort Study in the Province of Quebec, Canada.
    Clin Infect Dis. 2025 Oct 29:ciaf144. doi: 10.1093.
    >> Share

  25. KABORE JL, Laffont B, Diop M, Tardif MR, et al
    Real-World Effectiveness of Nirmatrelvir-Ritonavir in Preventing Coronavirus Disease 2019-Associated Hospitalization: A Population-Based Cohort Study in the Province of Quebec, Canada.
    Clin Infect Dis. 2025 Oct 29:ciaf145. doi: 10.1093.
    >> Share

  26. CALABRESE C, Wang Y, Duggal A, Huang S, et al
    Effectiveness of Nirmatrelvir/Ritonavir or Molnupiravir Use in Immunocompromised Patients on B-Cell-Depleting Therapy With COVID-19: A Target Trial Emulation Study.
    Clin Infect Dis. 2025 Oct 24:ciaf521. doi: 10.1093.
    >> Share

  27. PATEL K, Jaramillo-Underwood A, Karalius B, Yao TJ, et al
    Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes.
    Clin Infect Dis. 2025 Oct 22:ciaf538. doi: 10.1093.
    >> Share

  28. LE JN, Zhu W, Huang YA, Wei W, et al
    Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015-2023.
    Clin Infect Dis. 2025 Oct 16:ciaf581. doi: 10.1093.
    >> Share

  29. SERRANO-VILLAR S, Martin-Pedraza L, Tiraboschi J, Novella M, et al
    Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults with HIV (INSTINCT/GESIDA10918 Study).
    Clin Infect Dis. 2025 Oct 10:ciaf565. doi: 10.1093.
    >> Share

  30. KOETHE JR
    Tenofovir Alafenamide and Body Weight: Have We Finally Tipped the Scale?
    Clin Infect Dis. 2025 Oct 10:ciaf566. doi: 10.1093.
    >> Share

    September 2025
  31. ZHANG W, Terra SG, Weinstein EA, Bramson C, et al
    Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity.
    Clin Infect Dis. 2025 Sep 30:ciaf548. doi: 10.1093.
    >> Share

  32. MANN SC, Lykins D, Coyle RP, Witt MD, et al
    In the Mismatch: Viral Suppression Despite Low Tenofovir-Diphosphate in Dried Blood Spots in the Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort.
    Clin Infect Dis. 2025 Sep 17:ciaf509. doi: 10.1093.
    >> Share

  33. BECK IA, Boyce CL, Bishop MD, Oldroyd AR, et al
    HIV resistance to dolutegravir varies with co-administered agents.
    Clin Infect Dis. 2025 Sep 2:ciaf481. doi: 10.1093.
    >> Share

    August 2025
  34. FIGUEROA MI, Brites C, Cecchini D, Ramalho A, et al
    Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study.
    Clin Infect Dis. 2025 Aug 28:ciaf415. doi: 10.1093.
    >> Share

  35. WATERS LJ
    DOLCE: Sweet Success for Dolutegravir/Lamivudine?
    Clin Infect Dis. 2025 Aug 28:ciaf416. doi: 10.1093.
    >> Share

  36. ZHANG L, Wu X, He Y, Song Y, et al
    Impact of different INSTIs on BMI among people living with HIV who newly started ART in Shenzhen, China: a real-world data analysis.
    Clin Infect Dis. 2025 Aug 20:ciaf466. doi: 10.1093.
    >> Share

  37. NUTT CT, Lessells RJ, Muyindike WR, Johnson LS, et al
    Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries with the Highest Adult HIV Prevalence.
    Clin Infect Dis. 2025 Aug 11:ciaf444. doi: 10.1093.
    >> Share

    July 2025
  38. BROWN TT, Arao RF, Warsi M, Phanuphak N, et al
    Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083.
    Clin Infect Dis. 2025 Jul 1:ciaf221. doi: 10.1093.
    >> Share

    June 2025
  39. NYEIN PP, Borok M, Eriobu N, Kaplan R, et al
    A randomised trial to compare dolutegravir plus boosted darunavir versus recommended standard of care antiretroviral regimens in people with HIV-1, whose first-line non-nucleoside reverse transcriptase inhibitor therapy has failed: Final 96-week resul
    Clin Infect Dis. 2025 Jun 27:ciaf346. doi: 10.1093.
    >> Share

  40. VAN ZYL GU, Decloedt E, Jennings L, Kellermann T, et al
    A real-time urine tenofovir assay improves drug adherence among people with HIV with prior virologic failure in a randomized controlled trial.
    Clin Infect Dis. 2025 Jun 20:ciaf337. doi: 10.1093.
    >> Share

    May 2025
  41. AUDSLEY J, Avihingsanon A, Li X, Edwards R, et al
    Kinetics and predictors of Hepatitis B surface antigen (HBsAg) loss after commencing HBV-active antiretroviral therapy (ART) in the setting of HIV-and chronic HBV co-infection.
    Clin Infect Dis. 2025 May 31:ciaf281. doi: 10.1093.
    >> Share

  42. HAN WM, Ryom L, Sabin CA, Greenberg L, et al
    Risk of cancer in people with HIV experiencing varying degrees of immune recovery with sustained virological suppression on antiretroviral treatment for more than 2 years: an international, multicentre, observational cohort.
    Clin Infect Dis. 2025 May 15:ciaf248. doi: 10.1093.
    >> Share

    April 2025
  43. HAO J, Liu X, Wang D, Hu H, et al
    Transmitted Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance Among Newly Diagnosed Individuals in 31 Provincial-Level Administrative Divisions in China in 2023: A Cross-sectional Survey.
    Clin Infect Dis. 2025 Apr 29:ciaf159. doi: 10.1093.
    >> Share

  44. MONTEPIEDRA G, Aaron L, Theron G, McCarthy K, et al
    Hepatotoxicity Among People Living with HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics.
    Clin Infect Dis. 2025 Apr 16:ciaf198. doi: 10.1093.
    >> Share

    March 2025
  45. GARCIA-RUIZ DE MORALES AG, Suarez Robles M, Perez-Elias MJ, Negredo E, et al
    Metabolic Complications After Initiating BIC/FTC/TAF Versus DTG + 3TC in ART-naive Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study.
    Clin Infect Dis. 2025 Mar 28:ciae645. doi: 10.1093.
    >> Share

  46. PEREZ-VALERO I, Mata DC, Espejo AC, Gallo M, et al
    Real-world effectiveness and safety of BIC/FTC/TAF in comparison with other regimens in people with HIV starting therapy with AIDS-defining conditions. Results from the CORIS Cohort: The ACTUAS II Study.
    Clin Infect Dis. 2025 Mar 27:ciaf162. doi: 10.1093.
    >> Share

  47. ROCKSTROH JK, Paredes R, Cahn P, Molina JM, et al
    Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trial.
    Clin Infect Dis. 2025 Mar 13:ciaf077. doi: 10.1093.
    >> Share

  48. DE MIGUEL R, de Lagarde Sebastian M, Blanco Arevalo JL, Pinto-Martinez A, et al
    Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons with Historical Suspected or Confirmed Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicentre, Phase IIA Clinical Trial.
    Clin Infect Dis. 2025 Mar 7:ciaf100. doi: 10.1093.
    >> Share

    February 2025
  49. REGAN AK, Rowe SL, Sullivan SG, Coates MM, et al
    Coronavirus Disease 2019 Antiviral Medication Use Among Pregnant and Recently Pregnant US Outpatients.
    Clin Infect Dis. 2025 Feb 5:ciae580. doi: 10.1093.
    >> Share

  50. COLLIER M, Chouchana L, Frange P, Sibiude J, et al
    Risk of Neurodevelopmental Disorders in Children Exposed to Human Immunodeficiency Virus and Antiretrovirals In Utero: A National Cohort Study in France.
    Clin Infect Dis. 2025 Feb 5:ciae610. doi: 10.1093.
    >> Share

    January 2025
  51. GRENNAN T, Mohammed S, Edward J, Tattersall T, et al
    A pilot, randomized controlled trial of Dual Daily HIV and sexually transmitted infection pre-exposure prophylaxis using tenofovir disoproxil fumarate/emtricitabine and doxycycline in gay, bisexual and other men who have sex with men and transgender w
    Clin Infect Dis. 2025 Jan 30:ciaf043. doi: 10.1093.
    >> Share

  52. HUANG YS, Sun HY, Ho SY, Lin KY, et al
    Incidence and outcome of hepatitis D virus infection in people with HIV in the era of tenofovir-containing antiretroviral therapy.
    Clin Infect Dis. 2025 Jan 2:ciae655. doi: 10.1093.
    >> Share

    December 2024
  53. RAWSON JMO, Donaldson EF, O'Rear JJ, Harrington PR, et al
    Independent FDA Analyses of Nirmatrelvir/Ritonavir Resistance in the Phase 2/3 Trials EPIC-HR and EPIC-SR.
    Clin Infect Dis. 2024 Dec 17:ciae615. doi: 10.1093.
    >> Share

  54. BURMAN WJ, Hawkins KL
    Toward Evidence-based Recommendations for Laboratory Monitoring for Adolescents and Adults on Antiretroviral Therapy.
    Clin Infect Dis. 2024 Dec 10:ciae542. doi: 10.1093.
    >> Share

  55. SWINDELLS S
    Bookends.
    Clin Infect Dis. 2024 Dec 5:ciae554. doi: 10.1093.
    >> Share

    November 2024
  56. CLEMENT ME, Hanscom B, Haines D, Bazan JA, et al
    Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083.
    Clin Infect Dis. 2024 Nov 23:ciae572. doi: 10.1093.
    >> Share

  57. LANZ C, Meier J, Stockle M, Furrer H, et al
    HIV-1 low-level viremia predicts viral failure in participants on antiretroviral therapy in the Swiss HIV Cohort Study.
    Clin Infect Dis. 2024 Nov 21:ciae569. doi: 10.1093.
    >> Share

  58. HAMMOND J, Leister-Tebbe H, Gardner A, Abreu P, et al
    Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial.
    Clin Infect Dis. 2024 Nov 11:ciae551. doi: 10.1093.
    >> Share

    October 2024
  59. HICKEY MD, Gistand N, Grochowski J, Mayorga-Munoz F, et al
    48-week viral suppression rates in people with HIV starting long-acting CAB/RPV with initial viremia.
    Clin Infect Dis. 2024 Oct 5:ciae500. doi: 10.1093.
    >> Share

    September 2024
  60. FAIRHEAD C, Levi J, Ramesh N, Hill A, et al
    Results from systematic review and meta-analysis of the efficacy and safety of two-drug versus three-drug ( Tenofovir/Lamivudine/Dolutegravir; TLD) regimens for HIV treatment.
    Clin Infect Dis. 2024 Sep 30:ciae490. doi: 10.1093.
    >> Share

  61. JOLY V, Ferre VM, Le Hingrat Q, Peytavin G, et al
    Immuno-virological and Clinical Follow-up of Persons Living With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective Study.
    Clin Infect Dis. 2024 Sep 16:ciae447. doi: 10.1093.
    >> Share

  62. ANDERSON D, Ramgopal M, Hagins DP, Lee J, et al
    DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor-based Regimen Switch Strategy to Manage Integrase Inhibitor-related Weight Gain.
    Clin Infect Dis. 2024 Sep 4:ciae449. doi: 10.1093.
    >> Share

  63. EKE AC, Brummel SS, Aliyu MH, Stranix-Chibanda L, et al
    Lipid and glucose profiles in pregnant women with HIV on tenofovir-based antiretroviral therapy.
    Clin Infect Dis. 2024 Sep 2:ciae441. doi: 10.1093.
    >> Share

    August 2024
  64. GROENENDIJK AL, Miranda Afonso P, Wit F, Blaauw MJT, et al
    The risk of non-AIDS defining events is lower in ART-naive HIV controllers than in normal progressors on suppressive ART.
    Clin Infect Dis. 2024 Aug 29:ciae440. doi: 10.1093.
    >> Share

    July 2024
  65. KAUPPINEN KJ, Aho I, Sjoblom N, Tynninen O, et al
    Effect of Two Forms of Tenofovir on Duodenal Enterocytes - a Hypothesis for Different Effect of TDF and TAF on Body Weight and Plasma Lipids.
    Clin Infect Dis. 2024 Jul 23:ciae374. doi: 10.1093.
    >> Share

  66. FAUST JS, Meyerowitz-Katz G
    Is Paxlovid Still Worth It?
    Clin Infect Dis. 2024;79:111-114.
    >> Share

  67. FAIRHEAD C, Levi J, Hill A
    Challenges for novel antiretroviral development in an era of widespread TLD availability.
    Clin Infect Dis. 2024 Jul 11:ciae361. doi: 10.1093.
    >> Share

    June 2024
  68. YAN L, Bui D, Li Y, Rajeevan N, et al
    Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation.
    Clin Infect Dis. 2024 Jun 12:ciae202. doi: 10.1093.
    >> Share

  69. SKRIVANKOVA VW, Huwa J, Muula G, Chiwaya GD, et al
    Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia.
    Clin Infect Dis. 2024 Jun 7:ciae261. doi: 10.1093.
    >> Share

    May 2024
  70. ALEXANDRE M, Prague M, Lhomme E, Lelievre JD, et al
    Definition of Virological Endpoints Improving the Design of Human Immunodeficiency Virus (HIV) Cure Strategies Using Analytical Antiretroviral Treatment Interruption.
    Clin Infect Dis. 2024 May 31:ciae235. doi: 10.1093.
    >> Share

  71. PAN CQ, Zhu L, Yu AS, Zhao Y, et al
    Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate for Preventing Vertical Transmission in Chronic Hepatitis B Mothers: A Systematic Review and Meta-Analysis.
    Clin Infect Dis. 2024 May 28:ciae288. doi: 10.1093.
    >> Share

  72. KONU YR, Takassi E, Peytavin G, Dapam N, et al
    Pharmaco-virological outcomes and genotypic resistance profiles among children and adolescents receiving a DTG-based regimen in Togo.
    Clin Infect Dis. 2024 May 15:ciae278. doi: 10.1093.
    >> Share

  73. SHAH NS, Kityo C, Hughes MD, McCarthy C, et al
    Effectiveness of double-dose dolutegravir in people receiving rifampin-based tuberculosis treatment: an observational, cohort study of people with HIV from six countries.
    Clin Infect Dis. 2024 May 13:ciae269. doi: 10.1093.
    >> Share

  74. NYEIN PP, Petoumenos K, Borok M, Eriobu N, et al
    Associations between antiretroviral regimen and changes in blood pressure: results from the D2EFT study.
    Clin Infect Dis. 2024 May 9:ciae256. doi: 10.1093.
    >> Share

  75. ZHANG HL, Mock M, Bushman L, Anderson PL, et al
    Cumulative tenofovir exposure among patients with human immunodeficiency virus/hepatitis B co-infection with differential viral suppression.
    Clin Infect Dis. 2024 May 3:ciae241. doi: 10.1093.
    >> Share

    April 2024
  76. PEREZ-ALBA E, Iquize-Condori RC, Cantu-Hernandez JA, Alvarez-Villalobos NA, et al
    PrEP for Transgender People: A Systematic review.
    Clin Infect Dis. 2024 Apr 24:ciae226. doi: 10.1093.
    >> Share

  77. COYLE RP, Morrow M, Mann SC, Mainella V, et al
    Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons with HIV Receiving Tenofovir Alafenamide and Emtricitabine-based Antiretroviral Therapy (QUANTI-TAF).
    Clin Infect Dis. 2024 Apr 18:ciae212. doi: 10.1093.
    >> Share

  78. WOHL DA, Koethe JR, Sax PE, McComsey GA, et al
    Antiretrovirals and Weight Change: Weighing the Evidence.
    Clin Infect Dis. 2024 Apr 12:ciae191. doi: 10.1093.
    >> Share

  79. HILL A
    Which form of tenofovir should be used worldwide: TDF or TAF?
    Clin Infect Dis. 2024 Apr 12:ciae190. doi: 10.1093.
    >> Share

  80. DAMAS J, Munting A, Fellay J, Haerry D, et al
    Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide (TAF) in people with HIV.
    Clin Infect Dis. 2024 Apr 12:ciae189. doi: 10.1093.
    >> Share

    March 2024
  81. JAO J, Bonner LB, Dobinda K, Powis KM, et al
    Lower Insulin Sensitivity Through 36 Months of Life With in Utero HIV and Antiretroviral Exposure in Botswana: Results From the Tshilo Dikotla Study.
    Clin Infect Dis. 2024 Mar 26:ciae088. doi: 10.1093.
    >> Share

  82. LANDOVITZ RJ, Tao L, Yang J, de Boer M, et al
    HIV-1 Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Pooled Analysis From 72 Global Studies.
    Clin Infect Dis. 2024 Mar 14:ciae143. doi: 10.1093.
    >> Share

  83. LLIBRE JM, Jou A, Puig T
    High-level dolutegravir resistance selection on dolutegravir/lamivudine.
    Clin Infect Dis. 2024 Mar 11:ciae125. doi: 10.1093.
    >> Share

    February 2024
  84. SHAH MM, Joyce B, Plumb ID, Sahakian S, et al
    Combined protection of vaccination and nirmatrelvir-ritonavir against hospitalization in adults with COVID-19.
    Clin Infect Dis. 2024 Feb 27:ciae105. doi: 10.1093.
    >> Share

  85. SLAMA L, Barrett BW, Abraham AG, Palella FJ Jr, et al
    Incident Proteinuria differs by HIV Serostatus among Men with Pre-diabetes: The Multicenter AIDS Cohort Study.
    Clin Infect Dis. 2024 Feb 9:ciae065. doi: 10.1093.
    >> Share

    January 2024
  86. WANG R, Sun L, Wang X, Zhai Y, et al
    Rapid Initiation of Antiretroviral Therapy with Coformulated Bictegravir, Emtricitabine, Tenofovir Alafenamide Versus Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate in HIV-positive Men Who Have Sex with Men in China: Week 48 Results of the Mu
    Clin Infect Dis. 2024 Jan 17:ciae012. doi: 10.1093.
    >> Share

  87. URSENBACH A, Ruch Y, Hoellinger B, Fuchs A, et al
    Two cases of viral re-suppression after M184V + R263 K selection on DTG/3TC without treatment modification.
    Clin Infect Dis. 2024 Jan 9:ciae006. doi: 10.1093.
    >> Share

  88. HOFFMAN RM, Brummel S, Ziemba L, Chinula L, et al
    Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum.
    Clin Infect Dis. 2024 Jan 5:ciae001. doi: 10.1093.
    >> Share

  89. LEVY ME, Burrows E, Chilunda V, Pawloski PA, et al
    SARS-CoV-2 Antiviral Prescribing Gaps Among Non-Hospitalized High-Risk Adults.
    Clin Infect Dis. 2024 Jan 3:ciad796. doi: 10.1093.
    >> Share

    December 2023
  90. LAFONT E, Blez D, Bildan MA, Veyer D, et al
    Nirmatrelvir and Ritonavir combination in COVID-19 patients with advanced chronic kidney disease.
    Clin Infect Dis. 2023 Dec 30:ciad785. doi: 10.1093.
    >> Share

    November 2023
  91. VINIKOOR MJ, Hamusonde K, Muula G, Asombang M, et al
    Long-term hepatitis B and liver outcomes among adults taking tenofovir-containing antiretroviral therapy for HBV/HIV coinfection in Zambia.
    Clin Infect Dis. 2023 Nov 24:ciad654. doi: 10.1093.
    >> Share

  92. GAUSI K, Mugerwa H, Siccardi M, Montanha MC, et al
    Pharmacokinetics and safety of twice-daily ritonavir-boosted atazanavir with rifampicin.
    Clin Infect Dis. 2023 Nov 20:ciad700. doi: 10.1093.
    >> Share

  93. MISRA K, Huang JS, Udeagu CN, Forgione L, et al
    Pre-exposure prophylaxis (PrEP) use history in people with antiretroviral resistance at HIV diagnosis: Findings from New York City HIV surveillance and partner services, 2015-2022.
    Clin Infect Dis. 2023 Nov 17:ciad699. doi: 10.1093.
    >> Share

  94. SMITH-JEFFCOAT SE, Biddle JE, Talbot HK, Morrisey KG, et al
    Symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared to propensity score matched untreated individuals.
    Clin Infect Dis. 2023 Nov 14:ciad696. doi: 10.1093.
    >> Share

  95. MEYEROWITZ EA, Li Y
    Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses.
    Clin Infect Dis. 2023 Nov 9:ciad685. doi: 10.1093.
    >> Share

    October 2023
  96. AMICK AK, Eskibozkurt GE, Hosek SG, Flanagan CF, et al
    Daily Oral Human Immunodeficiency Virus (HIV) Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price.
    Clin Infect Dis. 2023 Oct 12:ciad566. doi: 10.1093.
    >> Share

    September 2023
  97. SHARMA I, Hill A
    Global HIV Incidence Analysis and Implications for Affordability using CAB-LA versus Continuous and Event-Driven Oral PrEP.
    Clin Infect Dis. 2023 Sep 4:ciad537. doi: 10.1093.
    >> Share

    August 2023
  98. GENTRY CA, Nguyen PN, Thind SK, Kurdgelashvili G, et al
    Characteristics and outcomes of US Veterans with immunocompromised conditions at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
    Clin Infect Dis. 2023 Aug 24:ciad504. doi: 10.1093.
    >> Share

  99. BERTON M, Bettonte S, Stader F, Decosterd L, et al
    Antiretroviral drug exposure and response in obese and morbidly obese people with HIV: a study combining modelling and Swiss HIV Cohort data.
    Clin Infect Dis. 2023 Aug 21:ciad495. doi: 10.1093.
    >> Share

  100. ZUCKERMAN NS, Bucris E, Keidar-Friedman D, Amsalem M, et al
    Nirmatrelvir resistance - de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure - a case report.
    Clin Infect Dis. 2023 Aug 19:ciad494. doi: 10.1093.
    >> Share

  101. NIU X, Drain PK
    Is Higher Adherence Required for Women using Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Preexposure Prophylaxis?
    Clin Infect Dis. 2023 Aug 17:ciad485. doi: 10.1093.
    >> Share

  102. CHAN GCK, Lui GCY, Wong CNS, Yip SST, et al
    Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019 (COVID-19).
    Clin Infect Dis. 2023 Aug 2:ciad371. doi: 10.1093.
    >> Share

    July 2023
  103. HAN WM, Apornpong T, Su Lwin HM, Thammapiwan S, et al
    Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis with liver fibrosis as predictors of new-onset Diabetes Mellitus in People living with HIV: A Longitudinal Cohort Study.
    Clin Infect Dis. 2023 Jul 21:ciad433. doi: 10.1093.
    >> Share

  104. ZINO L, Wit F, Rokx C, den Hollander JG, et al
    Outcomes of bariatric surgery in people with HIV: a retrospective analysis from ATHENA cohort.
    Clin Infect Dis. 2023 Jul 1:ciad404. doi: 10.1093.
    >> Share

    June 2023
  105. FAUST JS, Kumar A, Shah J, Khadke S, et al
    Oral Nirmatrelvir and Ritonavir for Covid-19 in Vaccinated, Non-Hospitalized Adults, Ages 18-50 Years.
    Clin Infect Dis. 2023 Jun 30:ciad400. doi: 10.1093.
    >> Share

  106. TSCHUMI N, Lerotholi M, Motaboli L, Mokete M, et al
    Two-year outcomes of treatment-experienced adults after programmatic transitioning to dolutegravir: longitudinal data from the VICONEL HIV cohort in Lesotho.
    Clin Infect Dis. 2023 Jun 26:ciad390. doi: 10.1093.
    >> Share

  107. WEST E, Zeeb M, Grube C, Kuster H, et al
    Sustained viral suppression with dolutegravir monotherapy over 192 weeks in patients starting combination antiretroviral therapy during primary HIV infection (EARLY-SIMPLIFIED): a randomized, controlled, multi-site, non-inferiority trial.
    Clin Infect Dis. 2023 Jun 20:ciad366. doi: 10.1093.
    >> Share

    May 2023
  108. DEL AMO J
    Question of Whether Tenofovir Disoproxil Fumarate/Emtricitabine Provides Protection Against Clinical Severity of Coronavirus Disease 2019.
    Clin Infect Dis. 2023;76:1735-1737.
    >> Share

  109. LETENDRE SL, Chen H, McKhann A, Roa J, et al
    Antiretroviral Therapy Intensification for Neurocognitive Impairment in HIV.
    Clin Infect Dis. 2023 May 15:ciad265. doi: 10.1093.
    >> Share

  110. WAALEWIJN H, Szubert AJ, Wasmann RE, Wiesner L, et al
    First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
    Clin Infect Dis. 2023 May 9:ciad267. doi: 10.1093.
    >> Share

  111. KABORE JL, Laffont B, Diop M, Tardif MR, et al
    Real-World Effectiveness of Nirmatrelvir/Ritonavir on Covid-19-Associated Hospitalization Prevention: A Population-Based Cohort Study in the Province of Quebec, Canada.
    Clin Infect Dis. 2023 May 7:ciad287. doi: 10.1093.
    >> Share

    April 2023
  112. ALVAREZ H, Mocroft A, Ryom L, Neesgaard B, et al
    Plasma HIV-1 RNA and CD4+ T-cell counts are determinants of virological non-suppression outcomes with initial integrase inhibitor-based regimens: A prospective RESPOND cohort study.
    Clin Infect Dis. 2023 Apr 13:ciad219. doi: 10.1093.
    >> Share

    March 2023
  113. WERBEL WA, Weld ED, Advani SD, Patel PK, et al
    Your outpatient has COVID-19: what are their treatment options in the current SARS-CoV-2 variant climate?
    Clin Infect Dis. 2023 Mar 31:ciad178. doi: 10.1093.
    >> Share

  114. MIKULSKA M, Sepulcri C, Dentone C, Magne F, et al
    Triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients.
    Clin Infect Dis. 2023 Mar 28:ciad181. doi: 10.1093.
    >> Share

  115. WANG P, Xing H, Zhang X, Yang J, et al
    Complexity Interactions between Nirmatrelvir/Ritonavir and Voriconazole in Patients with Coronavirus Disease 2019.
    Clin Infect Dis. 2023 Mar 21:ciad159. doi: 10.1093.
    >> Share

  116. LEA AN, Leyden WA, Sofrygin O, Marafino BJ, et al
    Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 (COVID-19) Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout.
    Clin Infect Dis. 2023 Mar 2:ciad084. doi: 10.1093.
    >> Share

  117. DEL AMO J
    Question of Whether Tenofovir Disoproxil Fumarate/Emtricitabine Provides Protection Against Clinical Severity of Coronavirus Disease 2019 (COVID-19).
    Clin Infect Dis. 2023 Mar 2:ciad086. doi: 10.1093.
    >> Share

    February 2023
  118. PANDIT JA, Radin JM, Chiang D, Spencer EG, et al
    The COVID-19 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated with Nirmatrelvir Plus Ritonavir Versus Untreated Controls.
    Clin Infect Dis. 2023 Feb 22:ciad102. doi: 10.1093.
    >> Share

    January 2023
  119. AVERY EF, Kleynhans JN, Ledergerber B, Schoepf IC, et al
    Leukocyte Count and Coronary Artery Disease Events in People with HIV: A Longitudinal Study.
    Clin Infect Dis. 2023 Jan 23:ciad033. doi: 10.1093.
    >> Share

  120. ANDERSON PL, Marzinke MA, Glidden DV
    Updating the adherence-response for oral F-TDF for PrEP among cisgender women.
    Clin Infect Dis. 2023 Jan 16:ciad021. doi: 10.1093.
    >> Share

  121. ZHAO Y, Griesel R, Omar Z, Simmons B, et al
    Initial supplementary dose of dolutegravir in second-line antiretroviral therapy: a non-comparative, double-blind, randomised placebo-controlled trial.
    Clin Infect Dis. 2023 Jan 16:ciad023. doi: 10.1093.
    >> Share

  122. BONAZZETTI C, Tazza B, Gibertoni D, Pasquini Z, et al
    Relationship between immune response to SARS-CoV2 vaccines and development of breakthrough infection in solid organ transplant recipients: the CONTRAST cohort.
    Clin Infect Dis. 2023 Jan 13:ciad016. doi: 10.1093.
    >> Share

    December 2022
  123. DE SALAZAR A, Vinuela L, Fuentes A, Teyssou E, et al
    Transmitted drug resistance to integrase based first-line HIV antiretroviral regimens in the Mediterranean Europe.
    Clin Infect Dis. 2022 Dec 26:ciac972. doi: 10.1093.
    >> Share

  124. VUORIO A, Kovanen PT, Raal F
    Statin Needs to be Continued During Paxlovid Therapy in COVID-19.
    Clin Infect Dis. 2022;75:2281-2282.
    >> Share

  125. UCHIKOBA S, Yamada G, Tsuzuki S
    Methodological Concerns Regarding a Retrospective Study With Real-World Data on Paxlovid in Israel.
    Clin Infect Dis. 2022;75:2278-2279.
    >> Share

  126. CHEN HY, Chang R, Wei JC
    Epidemiological Study of the Effectiveness of Paxlovid.
    Clin Infect Dis. 2022;75:2278.
    >> Share

  127. CHOUFANY M, Weiss L, Makinson A, Roul H, et al
    Decrease in CD4 count and risk of severe morbidity in PWH with controlled viral load after initiating cART between 2006 and 2018.
    Clin Infect Dis. 2022 Dec 17:ciac939. doi: 10.1093.
    >> Share

  128. BOSCH B, Akpomiemie G, Chandiwana N, Sokhela S, et al
    Weight and metabolic changes after switching from tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+DTG and TDF/FTC/efavirenz (EFV) to TDF/lamivudine (3TC)/DTG.
    Clin Infect Dis. 2022 Dec 15:ciac949. doi: 10.1093.
    >> Share

    November 2022
  129. THOMAS DL, Kiser JJ, Baum MM
    Long-Acting Treatments for Hepatitis B.
    Clin Infect Dis. 2022;75.
    >> Share

  130. BERENGUER J, Jarrin I, Bellon JM, Diez C, et al
    Obesity-related SNPs and weight gain following first-line antiretroviral therapy.
    Clin Infect Dis. 2022 Nov 8. pii: 6809103. doi: 10.1093.
    >> Share

  131. FORD ES, Simmons W, Karmarkar EN, Yoke LH, et al
    Successful treatment of prolonged, severe COVID-19 lower respiratory tract disease in a B-cell ALL patient with an extended course of remdesivir and nirmatrelvir/ritonavir.
    Clin Infect Dis. 2022 Nov 3. pii: 6795102. doi: 10.1093.
    >> Share

    October 2022
  132. WALSH BS, Kesselheim AS, Rome BN
    Medicaid Spending on Antiretrovirals from 2007-2019.
    Clin Infect Dis. 2022 Oct 21. pii: 6765227. doi: 10.1093.
    >> Share

  133. WATERS L, Assoumou L, Gonzalez-Cordon A, Rusconi S, et al
    Limited weight impact after switching from boosted protease inhibitors to dolutegravir in persons with HIV with high cardiovascular risk: a post hoc analysis of the 96-week NEAT-022 randomized trial.
    Clin Infect Dis. 2022 Oct 19. pii: 6763268. doi: 10.1093.
    >> Share

  134. JOHNSON KA, Okochi H, Arreguin M, Watabe J, et al
    Brief Report: Urine Tenofovir Levels Strongly Correlate with Virologic Suppression in Patients with HIV on Tenofovir Alafenamide-Based Antiretroviral Therapy.
    Clin Infect Dis. 2022 Oct 18. pii: 6762398. doi: 10.1093.
    >> Share

  135. HOFMANN E, Surial B, Boillat-Blanco N, Gunthard HF, et al
    HBV REPLICATION DURING TENOFOVIR THERAPY IS FREQUENT IN HIV/HBV-COINFECTION.
    Clin Infect Dis. 2022 Oct 15. pii: 6761485. doi: 10.1093.
    >> Share

  136. EPLING BP, Rocco JM, Boswell KL, Laidlaw E, et al
    Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
    Clin Infect Dis. 2022 Oct 6. pii: 6749408. doi: 10.1093.
    >> Share

    September 2022
  137. HERMANS LE, Umunnakwe CN, Lalla-Edward ST, Hebel SK, et al
    Point-Of-Care Tenofovir urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for HIV-1 Infection.
    Clin Infect Dis. 2022 Sep 22. pii: 6711553. doi: 10.1093.
    >> Share

  138. ELVSTAM O, Malmborn K, Elen S, Marrone G, et al
    Virologic failure following low-level viremia and viral blips during antiretroviral therapy: results from a European multicenter cohort.
    Clin Infect Dis. 2022 Sep 14. pii: 6696999. doi: 10.1093.
    >> Share

    August 2022
  139. PETTIT AC, Phillips PP, Kurbatova E, Vernon A, et al
    Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV (S31/A5349).
    Clin Infect Dis. 2022 Aug 30. pii: 6679254. doi: 10.1093.
    >> Share

  140. YIP TCF, Lui GCY, Lai MSM, Wong VWS, et al
    Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients.
    Clin Infect Dis. 2022 Aug 29. pii: 6678124. doi: 10.1093.
    >> Share

  141. NELSON BS, Tierney C, Persaud D, Jao J, et al
    Infants Receiving Very Early ART Have High CD4 Counts in the First Year of Life.
    Clin Infect Dis. 2022 Aug 29. pii: 6678126. doi: 10.1093.
    >> Share

  142. DIRAJLAL-FARGO S, Zhao C, Labbato D, Sattar A, et al
    Longitudinal changes in subclinical vascular disease in Ugandan youth with HIV.
    Clin Infect Dis. 2022 Aug 25. pii: 6675220. doi: 10.1093.
    >> Share

  143. MASIA M, Fernandez-Gonzalez M, Agullo V, Mascarell P, et al
    HIV-1 RNA levels in rectal and seminal compartments after switching to long-acting cabotegravir plus rilpivirine: a longitudinal study.
    Clin Infect Dis. 2022 Aug 20. pii: 6672706. doi: 10.1093.
    >> Share

  144. GANATRA S, Dani SS, Ahmad J, Kumar A, et al
    Oral Nirmatrelvir and Ritonavir in Non-hospitalized Vaccinated Patients with Covid-19.
    Clin Infect Dis. 2022 Aug 20. pii: 6672670. doi: 10.1093.
    >> Share

  145. DHARAN NJ, Jin F, Vaccher S, Bavinton B, et al
    Characteristics of HIV seroconversions in a large prospective implementation cohort study of oral HIV pre-exposure prophylaxis in men who have sex with men (EPIC-NSW).
    Clin Infect Dis. 2022 Aug 19. pii: 6671581. doi: 10.1093.
    >> Share

  146. SIBERRY GK, Mofenson LM, Calmy A, Reddy UM, et al
    Use of Ritonavir-boosted Nirmatrelvir in Pregnancy.
    Clin Infect Dis. 2022 Aug 17. pii: 6668958. doi: 10.1093.
    >> Share

    July 2022
  147. MONTEJANO R, de la Calle-Prieto F, Velasco M, Guijarro C, et al
    Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe COVID-19: The PANCOVID Randomized Clinical Trial.
    Clin Infect Dis. 2022 Jul 30. pii: 6652179. doi: 10.1093.
    >> Share

  148. MARTINEZ-SANZ J, Serrano-Villar S, Muriel A, Fraile LJG, et al
    Metabolic-related outcomes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in adults with HIV: a multicenter prospective cohort study.
    Clin Infect Dis. 2022 Jul 29. pii: 6651472. doi: 10.1093.
    >> Share

  149. LI H, Gao M, You H, Zhang P, et al
    Association of nirmatrelvir/ritonavir treatment on upper respiratory SARS-CoV-2 RT-PCR negative conversion rates among high-risk patients with COVID-19.
    Clin Infect Dis. 2022 Jul 23. pii: 6649232. doi: 10.1093.
    >> Share

  150. PESKO B, Deng A, Chan JD, Neme S, et al
    Safety, and Tolerability of Paxlovid (nirmatrelvir/ritonavir) in High Risk Patients.
    Clin Infect Dis. 2022 Jul 23. pii: 6649072. doi: 10.1093.
    >> Share

  151. SEKAGGYA-WILTSHIRE C, Nabisere R, Musaazi J, Otaalo B, et al
    Decreased dolutegravir and efavirenz concentrations with preserved virological suppression in patients with TB and HIV receiving high-dose rifampicin.
    Clin Infect Dis. 2022 Jul 21. pii: 6647783. doi: 10.1093.
    >> Share

  152. HSU HY, Chen HL, Chiang CL, Lai MW, et al
    Characterization of Hepatitis B Virus in Tenofovir-Treated and Untreated Chronically Infected Mothers and Their Immunoprophylaxis Failure Infants.
    Clin Infect Dis. 2022 Jul 5. pii: 6629403. doi: 10.1093.
    >> Share

  153. SHAH N, Esber A, Sean Cavanaugh J, Agaba P, et al
    Transitioning women to first-line preferred TLD regimen is lagging in Sub-Saharan Africa.
    Clin Infect Dis. 2022 Jul 5. pii: 6631203. doi: 10.1093.
    >> Share

    June 2022
  154. BOUCAU J, Uddin R, Marino C, Regan J, et al
    Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for COVID-19.
    Clin Infect Dis. 2022 Jun 23. pii: 6614635. doi: 10.1093.
    >> Share

  155. CARLIN AF, Clark AE, Chaillon A, Garretson AF, et al
    Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment.
    Clin Infect Dis. 2022 Jun 20. pii: 6611663. doi: 10.1093.
    >> Share

  156. RANGANATH N, O'Horo JC, Challener DW, Tulledge-Scheitel SM, et al
    Rebound Phenomenon after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk Persons.
    Clin Infect Dis. 2022 Jun 14. pii: 6607746. doi: 10.1093.
    >> Share

  157. CHAN P, Yoon B, Colby D, Kroon E, et al
    Immunological, Cognitive and Psychiatric Outcomes after Initiating EFV- and DTG-based Antiretroviral Therapy during Acute HIV Infection.
    Clin Infect Dis. 2022 Jun 10. pii: 6605344. doi: 10.1093.
    >> Share

  158. NAJJAR-DEBBINY R, Gronich N, Weber G, Khoury J, et al
    Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients.
    Clin Infect Dis. 2022 Jun 2. pii: 6599020. doi: 10.1093.
    >> Share

    May 2022
  159. SCEVOLA S, Imaz A, Cottrell ML, Niubo J, et al
    Doravirine Concentrations and HIV-1 RNA in the Genital Fluids of Virologically Suppressed Adults Switching to Doravirine plus Emtricitabine/Tenofovir Alafenamide.
    Clin Infect Dis. 2022 May 25. pii: 6591842. doi: 10.1093.
    >> Share

  160. BROWNE SH, Vaida F, Umlauf A, Tucker AJ, et al
    Supporting the Art: Medication Adherence Patterns in Persons Prescribed Ingestible Sensor-enabled Oral Pre-Exposure Prophylaxis to Prevent Human Immunodeficiency Virus (HIV) Infection.
    Clin Infect Dis. 2022 May 23:ciac280. doi: 10.1093.
    >> Share

  161. CHOW N, Wong D, Lai CL, Mak LY, et al
    Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion.
    Clin Infect Dis. 2022 May 20. pii: 6589784. doi: 10.1093.
    >> Share

  162. O'HALLORAN JA, Sahrmann J, Parra-Rodriguez L, Vo DT, et al
    Integrase Strand Transfer Inhibitors are Associated with Incident Diabetes Mellitus in People with HIV.
    Clin Infect Dis. 2022 May 6. pii: 6581614. doi: 10.1093.
    >> Share

    April 2022
  163. GARCIA-CREMADES M, Vucicevic K, Hendrix CW, Jayachandran P, et al
    Characterizing HIV-preventive, plasma tenofovir concentrations. A pooled participant-level data analysis from HIV pre-exposure prophylaxis (PrEP) clinical trials.
    Clin Infect Dis. 2022 Apr 26. pii: 6574602. doi: 10.1093.
    >> Share

    March 2022
  164. AMIN J, Vaccher S, Templeton DJ, Bavinton B B, et al
    Low prior exposure and incidence of hepatitis C in HIV negative gay and bisexual men taking PrEP: findings from the EPIC-NSW prospective implementation study.
    Clin Infect Dis. 2022 Mar 30. pii: 6555792. doi: 10.1093.
    >> Share

  165. BATEMAN M, Wolf A, Chimukangara B, Brust JCM, et al
    Adherence measured using electronic dose monitoring is associated with emergent antiretroviral resistance and poor outcomes in patients co-infected with HIV/AIDS and multidrug-resistant tuberculosis.
    Clin Infect Dis. 2022 Mar 30. pii: 6555759. doi: 10.1093.
    >> Share

  166. SARAVOLATZ LD, Depcinski S, Sharma M
    Molnupiravir and Nirmatrelvir-Ritonavir: Oral COVID Antiviral Drugs.
    Clin Infect Dis. 2022 Mar 4. pii: 6542722. doi: 10.1093.
    >> Share

  167. LLIBRE JM, Brites C, Cheng CY, Osiyemi O, et al
    Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With HIV-1: Week 48 Results From the Phase 3, Non-inferiority SALSA Randomiz
    Clin Infect Dis. 2022 Mar 2. pii: 6541246. doi: 10.1093.
    >> Share

    December 2021
  168. JOSEPH NT, Satten GA, Williams RE, Haddad LB, et al
    The Effect of Antiretroviral Therapy for the Treatment of HIV-1 in Pregnancy on Gestational Weight Gain.
    Clin Infect Dis. 2021 Dec 3. pii: 6448917. doi: 10.1093.
    >> Share

    January 2021
  169. AVETTAND-FENOEL V, Lechenadec J, Diallo MS, Fillion M, et al
    Initiating Antiretroviral Treatment Early in Infancy Has Long-term Benefits on the Human Immunodeficiency Virus Reservoir in Late Childhood and Adolescence.
    Clin Infect Dis. 2021 Jan 4. pii: 6062433. doi: 10.1093/cid/ciaa1931.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016